Graphene used for early cancer detection

HydroGraph Clean Power Inc. is a commercial manufacturer of high-quality nanomaterials whose graphene product has been selected and successfully trialed in Hawkeye Bio's biomedical sensor designed for the early detection of lung cancer.

Only the third company to be certified globally by the Graphene Council, HydroGraph is headquartered in Toronto, with a manufacturing facility in Kansas where the company has exclusive license from Kansas State University to produce both graphene and hydrogen through a patented detonation process.

Based on the purity and consistency of HydroGraph's graphene, the material was successfully trialed and selected for use in Hawkeye Bio's design. The Los Angeles-based medical technology company's unique biosensor detects inflammatory and autoimmune diseases, such as cancer, using samples of blood, urine, or saliva, with less invasive testing.

"Hawkeye Bio leverages HydroGraph's pristine graphene to manufacture pharmaceutical grade biosensors for the detection of lung cancer from a standard blood draw," said Hawkey CEO Andre de Fusco. "HydroGraph's manufacturing process reproducibly yields the 99.8% high purity and consistent geometry required for Hawkeye's ultra-sensitive diagnostic tests. The graphene biosensors' optimal signal-to-noise performance allows Hawkeye's blood test to pick up lung cancer in very early stage, asymptomatic individuals-the ones who can benefit the most from curative treatment."

Hawkeye's carbon-containing nanoscale sensor tracks complex changes in enzymes whose operations are the basis of human biological activity. This new technology is more sensitive and easier to operate than current screenings for a fraction of the cost. The intent is to promote easy, inexpensive check-ups for people not traditionally considered to be at risk.

It is the first in a coming lineup of biosensors designed for several different disease types and has the potential to markedly improve the field of cancer diagnostics. Founded in 2019, Hawkeye is a clinical-stage medical technology company with a team of technologists, medical doctors, and thoracic surgeons, over 15 years in liquid biopsy biotech development, and hands-on business and regulatory experience across operations in the U.S. as well as Europe and Asia.

"After several years of working together with Hawkeye, we have developed a strong partnership and are thrilled that our graphene helped bring their biosensor to market to save lives," said HydroGraph Clean Power CEO Stuart Jara.

The global biosensor market is expected to reach $60 billion by 2032.